Lataa...
Feasibility and attractiveness of indication value-based pricing in key EU countries
Indication value-based pricing (IBP) has been proposed in the United States as a tool to capture the differential value of drugs across indications or patient groups and is in the early phases of implementation. In Europe, no major country has experimented with IBP or is seriously discussing its use...
Tallennettuna:
| Julkaisussa: | J Mark Access Health Policy |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Co-Action Publishing
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4864834/ https://ncbi.nlm.nih.gov/pubmed/27226845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v4.30970 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|